Blueprint issues
December 14, 2011
COMPLEMENTARY medicines
company Flordis has taken issue
with the TGA’s new Blueprint (PD
12 Dec) saying it lets unproven
complementary medicines and
“fly-by-night promoters of these
products” off the hook.
“The reforms announced by the
Therapeutic Goods Administration
to complementary medicines do
not go far enough, and continue to
allow unproven products to gain
equal footing with those that have
undergone rigorous clinical trials,
said Flordis Managing Director,
Craig Weller.
“A very small number of
companies who are undertaking
clinical trials for their products and
who demonstrate their efficacy to
patients derive no benefit from
this investment.
“Their products are lumped in
with a multitude of unproven,
complementary medicines and
treatments,” he added.
Weller added that Blueprint let
consumers down because as more
people are embracing natural
medicines, they have no way of
knowing which products have been
properly assessed by the TGA.
“It is time that we adopted a
system of labelling that would help
consumers to identify those
products that the TGA has
assessed as holding evidence for
their efficacy,” he said.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Dec 11To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Dec 11
